Patents by Inventor Matthew Jude Sharp

Matthew Jude Sharp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process of preparing arylethanoldiamines
    Patent number: 7709677
    Abstract: An improved process for preparing arylethanoldiamines is described. Compounds of this type are known to be useful as agonists at atypical beta-adrenoceptors (also known as beta-3-adrenoceptors).
    Type: Grant
    Filed: August 12, 2008
    Date of Patent: May 4, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Jason William Beames Cooke, Bobby Neal Glover, Ronnie Maxwell Lawrence, Matthew Jude Sharp, Maria Fumiko Tymoschenko
  • PROCESS
    Publication number: 20080306278
    Abstract: An improved process for preparing arylethanoldiamines is described. Compounds of this type are known to be useful as agonists at atypical beta-adrenoceptors (also known as beta-3-adrenoceptors).
    Type: Application
    Filed: August 12, 2008
    Publication date: December 11, 2008
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Jason William Beames Cooke, Bobby Neal Glover, Ronnie Maxwell Lawrence, Matthew Jude Sharp, Maria Fumiko Tymoschenko
  • Process
    Patent number: 7425639
    Abstract: An improved process for preparing arylethanoldiamines is described. Compounds of this type are known to be useful as agonists at a typical beta-adrenoceptors (also known as beta-3-adrenoceptors).
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: September 16, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Jason William Beames Cooke, Bobby Neal Glover, Ronnie Maxwell Lawrence, Matthew Jude Sharp, Maria Fumiko Tymoschenko
  • Process
    Publication number: 20040077868
    Abstract: An improved process for preparing arylethanoldiamines is described. Compounds of this type are known to be useful as agonists at a typical beta-adrenoceptors (also known as beta-3-adrenoceptors).
    Type: Application
    Filed: July 31, 2003
    Publication date: April 22, 2004
    Inventors: Jason William Beames Cooke, Bobby Neal Glover, Ronnie Maxwell Lawrence, Matthew Jude Sharp, Maria Fumiko Tymoschenko
  • Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to PPAR-gamma
    Patent number: 6294580
    Abstract: A compound having formula (I), wherein A is selected from the group consisting of: (i) phenyl, wherein said phenyl is optionally substituted by one or more halogen atoms, C1-6alkyl, C1-3alkoxy, C1-3fluoroalkoxy, nitrile, or —NR7R8 where R7 and R8 are independently hydrogen or C1-3alkyl; (ii) a 5- or 6-membered hetrocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur; and (iii) a fused bicyclic ring (a), wherein ring C represents a heterocyclic group as defined in point (ii) above, which bicyclic ring is attached to group B via a ring atom of ring C; B is selected from the group consisting of: (iv) C1-6alkylene; (v) —MC1-6alkylene or C1-6alkyleneMC1-6alkylene, wherein M is O, S, or —NR2 wherein R2 represents hydrogen or C1-3alkyl; (vi) a 5- or 6-membered heterocyclic group containing at least one nitrogen heteroatom and optionally at least one further heteroatom selected from oxygen, nitrogen and sulfur and optionally substituted by C1-3alkyl; and (vii) H
    Type: Grant
    Filed: August 25, 1998
    Date of Patent: September 25, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Timothy Mark Willson, Robert Anthony Mook, Istvan Kaldor, Brad Richard Henke, David Norman Deaton, Jon Loren Collins, Jeffrey Edmond Cobb, Marcus Brackeen, Matthew Jude Sharp, John Mark O'Callaghan, Greg Alan Erickson, Grady Evan Boswell
  • Synthesis of acridine derivative multidrug-resistant inhibitors
    Patent number: 6248891
    Abstract: Synthesis of the MDRI of formula (I) from intermediates of acridone acid of formula (II) and aminophenethyl isoquinoline of formula (III), via steps including coupling and conversion to yield the MDRI of formula (I).
    Type: Grant
    Filed: January 19, 2000
    Date of Patent: June 19, 2001
    Assignee: Glaxo Wellcome, Inc.
    Inventors: Matthew Jude Sharp, Catherine J. Mader, Calum Strachan